LanroNET - A Non-Interventional Prospective Study to Assess the Resource Utilization and Cost of Lanreotide Autogel 120 mg in Population of Polish Patients with Symptomatic Neuroendocrine Tumors.

CONCLUSIONS: LanroNET is the first two-year observational study of patients with symptomatic NET evaluating the cost of every-day clinical practice and lanreotide autogel treatment in Poland. PMID: 30132588 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30132588?dopt=Abstract

Source: Endokrynologia Polska - August 22, 2018 Category: Endocrinology Authors: Orlewska E, Kos-Kudła B, Kamiński G, Budlewski T, Jessa-Jabłońska M, Houchard A, Bednarczuk T Tags: Endokrynol Pol Source Type: research

More News: Brain | Endocrinology | Neurology | Poland Health | Study